Foundation Medicine, Bristol Myers Squibb Expand CDx Partnership to Investigational Cancer Drug
The companies are working to establish FoundationOne CDx as a companion diagnostic for BMS's investigational tyrosine kinase inhibitor repotrectinib.
Guardant Health Licenses Genomic Cancer Assays to Adicon for Testing in China
Under the agreement, Adicon will provide biopharmaceutical companies conducting clinical trials in China access to Guardant's tissue and liquid biopsy tests.
Roche, Bristol Myers Squibb Partner on Digital Pathology Algorithms, Assays for Cancer Diagnosis
Under the collaboration, Roche is developing an artificial intelligence-based image analysis algorithm to help pathologists interpret its Ventana PD-L1 (SP142) Assay.
Genomenon, Inozyme Collaborate on MDx Effort for ENPP1 Deficiency
The companies hope to deliver AI-powered data to labs and clinicians to diagnose and treat a rare calcification disorder.
Thermo Fisher Scientific to Acquire Contract Research Organization PPD for $17.4B
Thermo Fisher will acquire PPD for $47.50 per share for a total price of $17.4 billion, plus the assumption of approximately $3.5 billion in debt.